Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 7, 2010; 16(37): 4697-4703
Published online Oct 7, 2010. doi: 10.3748/wjg.v16.i37.4697
Figure 2
Figure 2 Serum levels of carbohydrate antigen 19-9 and matrix metalloproteinase-7 in cholangiocarcinoma and control (benign biliary tract disease) patients. A: Box plots comparing levels of carbohydrate antigen 19-9 (CA19-9); B: Matrix metalloproteinase-7 (MMP7) between cholangiocarcinoma and control patients are illustrated; C: Box plots comparing levels of CA19-9; D: MMP7 between early and advanced stages of cholangiocarcinoma and controls are illustrated. Levels of MMP7 are presented as ng/mL, while CA19-9 is presented with the log data to accommodate the wide range. (bMann-Whitney U, P < 0.001 vs control; dStudent's t-test, P < 0.001 vs control; eKruskal Wallis test, P < 0.001 vs control; fANOVA, P < 0.001 vs control).